Summary
Patients with objectively measurable soft tissue sarcoma, bone sarcoma, or mesothelioma who had failed at least one prior chemotherapy regimen received either bleomycin (20 U/M22 i.v. day 1 each week), chlorozotocin (150 mg/M2 i.v. q6 weeks), MGBG (500 mg/M2 i.v. each week, escalated in 50 mg/M2 weekly increments to a maximum dose of 700 mg/M2), or bruceantin (5.5 mg/M2 days 1, 8, 15, and 22, with cycles repeated every 6 weeks). One hundred eighty patients were evaluable: 53 on bleomycin, 51 on chlorozotocin, 38 on MGBG, and 38 on bruceantin. Two partial responses resulted from bleomycin, and one each from chlorozotocin and MGBG. Both responders on bleomycin had mesothelioma. Seventy-four percent of the patients were of ECOG performance status 0 or 1, and over half on each arm had moderate or worse toxicity. At these doses and schedules, none of the four drugs tested was active against previously treated sarcomas. Bleomycin, however, should be considered for further evaluation in mesothelioma patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blum RH, Carter SK, Agre K: A clinical review of bleomycin — a new antineoplastic agent. Cancer 31:903–914, 1973
Cohen MH, Pocock SJ, Savlov ED, Lerner HJ, Colsky J, Regelson W, Carbone PP: Phase I-II trial of intramuscularly administered bleomycin. Eur J Cancer 13:49–53, 1977
Schein PS, Panasci L, Woolley PV, Anderson T: Pharmacology of chlorozotocin (NSC-178248), a new nitrosourea antitumor agent. Cancer Treat Rep 60:801–805, 1976
Krokan H, Eriksen A: DNA synthesis in HeLa cells and isolated nuclei after treatment with an inhibitor of spermidine synthesis, methyl glyoxal bis(guanylhydrazone). Eur J Biochem 72:501–508, 1977
Morris DR, Jorstad CM, Seyfried CE: Inhibition of the synthesis of polyamines and DNA in activated lymphocytes by a combination of α-methylornithine and methylglyoxal bis(guanylhydrazone). Cancer Res 37:3169–3172, 1977
Liao L-L, Kupchan SM, Horwitz SB: Mode of action of the antitumor compound bruceantin, an inhibitor of protein synthesis. Mol Pharmacol 12:167–176, 1976
Kupchan SM, Britton RW, Ziegler MF, Sigel CW: Bruceantin, a new potent antileukemic simaroubolide from brucea antidysenterica. J Org Chem 38:178–179, 1973
Kupchan SM, Britton RW, Lacadie JA, Ziegler MF, Sigel CW: The isolation and structural elucidation of bruceantin and bruceantinol, new potent antileukemic quassinoids from brucea antidysenterica. J Org Chem 40:648–654, 1975
Zelen M: The randomization and stratification of patients to clinical trials. J Chron Dis 27:365–375, 1974
Schoenfeld DA, Rosenbaum C, Horton J, Wolter JM, Falkson G, DeConti RC: A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 50:2757–2762, 1982
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958
Talley RW, Samson MK, Brownlee RW, Samhouri AM, Fraile RJ, Baker LH: Phase II evaluation of chlorozotocin (NSC-178248) in advanced human cancer. Eur J Cancer 17:337–343, 1981
Mouridsen HT, Bramwell VHC, Lacave J, Metz R, Vendrik C, Hild J, McCreanney J, Sylvester R: Treatment of advanced soft tissue sarcomas with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group. Cancer Treat Rep 65:509–511, 1981
Sordillo PP, Magill GB, Gralla RJ: Chlorozotocin: phase II evaluation in patients with advanced sarcomas. Cancer Treat Rep 65:513–514, 1981
Presant CA, Bartolucci AA, The Southeastern Cancer Study Group: Phase II evaluation of chlorozotocin in metastatic sarcomas. Med Pediatr Oncol 12:25–27, 1984
Lerner H, Amato D, Shiraki M, Borden E: A prospective study of adriamycin programs in malignant mesothelioma. (Abstract) Proc Am Soc Clin Oncol 2:230, 1983
Chahinian AP, Szrajer L, Beranek JT, Holland JF: Treatment of human malignant mesothelioma xenografts in nude mice. (Abstract) Proc Am Assoc Cancer Res 21:289, 1980
Chahinian AP, Norton L, Holland JF, Szrajer L, Hart RD: Experimental and clinical activity of mitomycin C and cisdiamminedichloroplatinum in malignant mesothelioma. Cancer Res 44:1688–1692, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Amato, D.A., Borden, E.C., Shiraki, M. et al. Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma. Invest New Drugs 3, 397–401 (1985). https://doi.org/10.1007/BF00170765
Issue Date:
DOI: https://doi.org/10.1007/BF00170765